Novo Nordisk announced that Wegovy® has been approved in China for long-term weight management, targeting patients with a BMI of 30kg/m² and at least one weight-related comorbidity.
The approval comes as the company plans a $4.1 billion expansion of its US manufacturing capacity.
On 17 April 2024, Biocon announced the signing of an exclusive licensing and supply agreement to provide generic Ozempic® (semaglutide) in Brazil. Earlier in the month, on April 10 2024, Boston-based Ginkgo Bioworks announced an expansion of its partnership with Novo Nordisk aimed at enhancing the manufacturing processes for Novo Nordisk’s medications, particularly those targeting chronic diseases like diabetes and obesity. Meanwhile, on 2 April 2024, Hangzhou Jiuyan Gene Engineering announced that its Chinese application for Jiyoutai™, a biosimilar to Novo Nordisk’s Ozempic® (semaglutide) for type 2 diabetes, had been accepted.